Paweł Kawalec

Summary

Affiliation: Jagiellonian University
Country: Poland

Publications

  1. pmc Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland
    Arch Med Sci 8:767-75. 2012
  2. pmc Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland Centrum HTA Sp z o o Sp komandytowa, Krakow, Poland
    PLoS ONE 8:e76587. 2013
  3. pmc The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, 20 Grzegorzecka St, 31 531, Krakow, Poland
    Clin Rheumatol 32:1415-24. 2013
  4. ncbi request reprint [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu
    Pol Merkur Lekarski 34:332-8. 2013
  5. ncbi request reprint [Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Wydział Nauk o Zdrowiu, Instytut Zdrowia Publicznego, Zaklad Gospodarki Lekiem
    Pol Merkur Lekarski 35:10-3. 2013
  6. ncbi request reprint [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results]
    Paweł Kawalec
    Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu UJ, ul Grzegorzecka 20, Krakow
    Pneumonol Alergol Pol 81:95-104. 2013
  7. doi request reprint Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project
    Nevena Sović
    Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Krakow, Poland
    Kardiol Pol 71:702-11. 2013
  8. doi request reprint Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
    Przemysław Holko
    Centrum HTA, Krakow, Poland
    Expert Rev Anticancer Ther 14:63-73. 2014

Collaborators

  • Maria Boratynska
  • Przemysław Holko
  • Nevena Sović
  • Renata Wolfshaut-Wolak
  • Piotr Jankowski
  • Alejandra Duenas
  • Andrzej Pajak
  • Kalina Kawecka-Jaszcz
  • Urszula Stepaniak

Detail Information

Publications11

  1. pmc Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland
    Arch Med Sci 8:767-75. 2012
    ..It is assumed to be associated with less adverse events than conventional docetaxel-based chemotherapy...
  2. pmc Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland Centrum HTA Sp z o o Sp komandytowa, Krakow, Poland
    PLoS ONE 8:e76587. 2013
    ..Nevirapine belongs to the group of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is commonly administered in first-line treatment of HIV infection...
  3. pmc The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, 20 Grzegorzecka St, 31 531, Krakow, Poland
    Clin Rheumatol 32:1415-24. 2013
    ..In addition, tofacitinib might provide an effective treatment option compared to intravenous or subcutaneous biological DMARDs, as suggested by the result of the comparison made regarding tofacitinib vs. adalimumab ACR50 response rate...
  4. ncbi request reprint [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu
    Pol Merkur Lekarski 34:332-8. 2013
    ..z o.o.) from 110 to 200 days, in the high risk patients group after kidney transplant (seronegative recipient and infected donor, D+/R-). The analysis was performed from the Polish healthcare payer's perspective...
  5. ncbi request reprint [Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Wydział Nauk o Zdrowiu, Instytut Zdrowia Publicznego, Zaklad Gospodarki Lekiem
    Pol Merkur Lekarski 35:10-3. 2013
    ....
  6. ncbi request reprint [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results]
    Paweł Kawalec
    Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu UJ, ul Grzegorzecka 20, Krakow
    Pneumonol Alergol Pol 81:95-104. 2013
    ..The aim of this study is a comparison of the clinical effectiveness of conestat alfa, human C1 esterase inhibitor (C1INH), and icatibant in the treatment of acute angioedema attacks in adults with HAE...
  7. doi request reprint Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project
    Nevena Sović
    Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Krakow, Poland
    Kardiol Pol 71:702-11. 2013
    ..However, introducing them broadly into clinical practice would have a significant impact on the healthcare budget, and requires careful consideration...
  8. doi request reprint Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
    Przemysław Holko
    Centrum HTA, Krakow, Poland
    Expert Rev Anticancer Ther 14:63-73. 2014
    ..Accounting for crossover treatment in control patients improves sipuleucel-T's value (US$132,000 per QALY saved) although further investigation is necessary. ..